|
Patent landscape, scope, and claims summary: |
US Patent 8,168,593 Landscape Analysis: Netrin-4 SEQ ID NO: 12 Peptide, Nucleic Acid SEQ ID NO: 11, and Anti-VEGF Combination Claims
US 8,168,593 is claim-dense around a single defined Netrin-4 fragment (peptide SEQ ID NO: 12) and its corresponding nucleic acid (SEQ ID NO: 11), then expands protection to expression constructs (vector/host) and a formulation claim that expressly combines the peptide with anti-VEGF drugs (bevacizumab, pegaptanib, ranibizumab, and “any other anti-VEGF agent”). The most commercially relevant exposure is whether any competitor’s Netrin-4 fragment mimic, antibody/peptide-derived modality, oligonucleotide therapy, or gene delivery product uses the same sequences and the same defined therapeutic combination concept with anti-VEGF.
US 8,168,593: What do the claims cover (and where are the practical enforcement choke points)?
Direct core coverage
- Claim 1: isolated peptide fragment of Netrin-4 defined by SEQ ID NO: 12.
- Claim 4/5: isolated nucleic acid defined by SEQ ID NO: 11 that codes for the SEQ ID NO: 12 peptide.
- Claim 6/7/8/9: recombinant vector containing SEQ ID NO: 11, vector types including plasmid/cosmid/phage/virus DNA, and host organism transformed by the vector, with host broadly including viral, bacterial, yeast, fungus, plant, or mammalian cells.
- Claim 2/11: pharmaceutical composition containing SEQ ID NO: 12 peptide (or a nucleic acid coding for it) in a pharmaceutically acceptable vehicle.
- Claim 3: pharmaceutical composition with the SEQ ID NO: 12 peptide plus an anti-VEGF agent selected from bevacizumab, pegaptanib, ranibizumab, or any other anti-VEGF agent.
Immediate enforcement choke points
- Sequence identity is the gate. Independent claim 1 and key dependent claim 2 hinge on peptide SEQ ID NO: 12. Design-around efforts typically target:
- different Netrin-4 fragments that retain function but alter sequence boundaries,
- peptide analogs with substitutions that change the amino-acid sequence,
- non-peptide modalities (e.g., antibodies to Netrin-4, small molecules affecting Netrin-4 signaling).
- Nucleic acid claims hinge on coding sequence, not merely function. Claim 4/5 require the nucleotide sequence SEQ ID NO: 11. Even if a developer uses a synonymous coding strategy, whether it avoids SEQ ID NO: 11 depends on what the patent treats as the “nucleotide sequence” (the literal sequence matters in an isolated nucleic acid claim).
- Vector/host breadth is high, but it is still constrained by inclusion of SEQ ID NO: 11. Claim 7 includes broad vector classes (plasmid/cosmid/phage/virus DNA). That breadth matters mainly if the competitor uses SEQ ID NO: 11 in any expression construct.
- The combination claim adds a licensing stickiness lever but remains sequence-constrained. Claim 3 is commercially meaningful because anti-VEGF products are entrenched. Still, the formulation must include the SEQ ID NO: 12 peptide as the active ingredient; using a different Netrin-4 fragment weakens claim 3’s direct coverage.
Which Netrin-4 target product types could infringe US 8,168,593 without using the exact same sequences?
High-risk infringers
- Any developer selling a peptide therapeutics product where the active is precisely the SEQ ID NO: 12 peptide (Claim 1 and Claim 2).
- Any developer selling or licensing a gene therapy or DNA/RNA expression modality where the active genetic element is exactly SEQ ID NO: 11 (Claims 4/5/10/11 and vector/host claims).
- Any developer using SEQ ID NO: 12 peptide in combination formulations with anti-VEGF agents that map to bevacizumab, pegaptanib, ranibizumab, or other anti-VEGF agents (Claim 3).
Lower-risk (but not automatically safe) design-around categories
- Different Netrin-4 fragment boundaries. If a product uses a fragment of Netrin-4 with different amino acids than SEQ ID NO: 12, it avoids the literal requirement in Claims 1/2/3/11.
- Amino-acid substitutions or conservative analogs. Even single-residue changes can evade a strict SEQ ID claim.
- Different nucleic acids for the same protein. If a competitor uses a different coding DNA (even if it encodes the same peptide), it can avoid Claim 5 if SEQ ID NO: 11 is not used literally.
- Non-nucleic-acid expression strategies. CRISPR editing that induces expression of the peptide indirectly is still a vector/host question only if the claim reads on the recombinant vector containing SEQ ID NO: 11. A system that does not include the specified sequence literal may avoid.
- Protein-sequestering antibodies or receptor antagonists. Those may not read on an isolated peptide fragment and typically do not use SEQ ID NO: 12 as an active ingredient.
How strong is the patent estate for US 8,168,593 given its claim construction signals (sequence-defined peptide and nucleic acid)?
Strength drivers
- The claims use explicit sequence IDs for peptide and nucleic acid. Courts typically treat sequence-defined claims as clear subject matter, which reduces ambiguity in scope.
- The breadth of dependent claims (vector types, host organism taxonomies, formulation with anti-VEGF agents) increases coverage for common manufacturing pathways.
Strength limiters
- Enforceability and practical scope depend on how cleanly competitors can differentiate:
- exact sequence matching versus conservative variants,
- delivery modality differences (especially whether any product can plausibly avoid containing the precise nucleic acid sequence).
- Combination claim 3 may create licensing leverage, but enforcement still requires use of the SEQ ID NO: 12 peptide as active ingredient, which is a narrower anchor than an “anti-VEGF plus Netrin-4 pathway modulation” concept.
Commercial implication
- The estate’s monetization path, based on these claims alone, is likely to target developers who:
- run clinical programs with peptide SEQ ID NO: 12 or genetic elements with nucleotide SEQ ID NO: 11,
- seek label expansion using anti-VEGF combo regimens.
When does US 8,168,593 lose exclusivity for products that use SEQ ID NO: 12 or SEQ ID NO: 11?
Answer constrained by missing patent metadata. Patent expiration depends on filing date, priority chain, and term adjustments (including PTA/PTE). The claim text alone does not provide the filing/priority date or any statutory term modifications. Without those facts, a correct exclusivity timeline cannot be produced.
What is the Orange Book status of US 8,168,593 and its Netrin-4 peptide/nucleic acid claims?
Answer constrained by missing bibliographic and Orange Book listing data. Orange Book status is product- and NDA/ANDA-code dependent. The claim text does not identify any NDA/ANDA, listed drug, or patent listing number. Without those details, the Orange Book status cannot be stated accurately.
What formulations are protected by US 8,168,593 (alone and with anti-VEGF agents)?
Protected formulation classes
- Peptide formulation: Claim 2 and Claim 11 language indicates vehicle-based pharmaceutical compositions.
- Active: peptide SEQ ID NO: 12 (Claim 2) or nucleic acid encoding it (Claim 11).
- Combination formulation with anti-VEGF:
- Claim 3 explicitly names bevacizumab, pegaptanib, ranibizumab, and “any other anti-VEGF agent.”
What this means for dosage form strategy
- The claims, as provided, do not specify route (intravitreal, IV, topical), dosage form (solution, lyophilized, implant), or controlled-release system.
- As a practical licensing and infringement risk matter, any vehicle-based formulation where the active ingredient is SEQ ID NO: 12 remains inside Claim 2 and Claim 3 if an anti-VEGF agent is co-administered within the claimed formulation.
How does US 8,168,593 compare with typical Netrin-4 IP: is it a platform patent or a sequence-specific patent?
US 8,168,593 is fundamentally sequence-specific rather than pathway-platform.
- The scope is anchored to literal sequences:
- peptide SEQ ID NO: 12,
- nucleotide sequence SEQ ID NO: 11,
- recombinant vectors containing SEQ ID NO: 11.
- This is different from broader patents that cover:
- antibodies to Netrin-4,
- general Netrin-4 agonists/antagonists,
- generic “modulators of Netrin-4 signaling” without sequence definition.
Net effect: the strongest competitive constraint comes from any program that uses the same sequences and not merely the same target biology.
Which companies are likely constrained by US 8,168,593 based on anti-VEGF combination use-cases?
Answer constrained by missing prosecution/assignee and prosecution history. The claims supplied do not identify assignees, inventors, or co-pending licenses that would allow a credible mapping to specific competitors. Without assignment and bibliographic data, naming likely constrained companies would risk incorrect attribution.
What patent litigation risks exist for Netrin-4 peptide/gene programs under US 8,168,593?
Answer constrained by missing litigation docket data. Claim text does not contain case identifiers, enforcement posture, or prior Paragraph IV equivalents (for biologics and gene therapies, the analog is not always Paragraph IV). Without case citations, filing/settlement information cannot be stated.
What generic entry risks exist for US 8,168,593-covered products?
Sequence-defined claims affect generic risk differently depending on modality:
- For peptide-based products (Claim 1/2): a “generic peptide” concept is sequence- and manufacturing-dependent. If the approved product’s active is literally SEQ ID NO: 12 and the generic seeks to replicate the same peptide, the sequence-defined claim can block entry even if other excipients differ.
- For nucleic acid/gene delivery (Claim 4/5/10/11): “generic gene therapy” is rarely straightforward. The entry risk turns on whether the exact nucleotide sequence SEQ ID NO: 11 (and the relevant construct/host context) is used.
Critical take: the sequence anchors make generic avoidance plausible mainly through design changes to peptide and/or nucleotide sequences, or via different modalities that avoid the sequence use in the claims.
How do the claims interact with biosimilar pathways (if the SEQ ID NO: 12 product is treated as a biologic)?
US 8,168,593 includes peptide and gene constructs, not antibodies or conventional biologic mAbs. If a product using SEQ ID NO: 12 peptide were regulated under a biologics framework, biosimilar design would still face sequence match constraints in Claims 1/2/3/11. A biosimilar would need to replicate the peptide active ingredient; sequence divergence is a primary design-around mechanism.
Claim-by-claim infringement map: what must a competitor do to avoid each element?
| Claim |
Claim element (from provided text) |
Literal infringement requires |
Practical design-around lever |
| 1 |
Isolated Netrin-4 fragment = SEQ ID NO: 12 |
Use/offer/sell an isolated peptide that is exactly SEQ ID NO: 12 |
Alter peptide sequence or use different fragment boundaries/analogs |
| 2 |
Composition with peptide SEQ ID NO: 12 + vehicle |
A formulation where active is SEQ ID NO: 12 peptide |
Change active peptide sequence |
| 3 |
Composition with peptide SEQ ID NO: 12 + anti-VEGF (bevacizumab/pegaptanib/ranibizumab/any other anti-VEGF) |
SEQ ID NO: 12 peptide is active and an anti-VEGF agent is included |
Avoid peptide SEQ ID NO: 12 or avoid combining into the claimed composition |
| 4 |
Isolated nucleic acid coding SEQ ID NO: 12 peptide |
Use of the specific nucleic acid that “codes for” the peptide |
Use a different coding nucleotide sequence (if it does not match SEQ ID NO: 11) |
| 5 |
Nucleic acid = SEQ ID NO: 11 |
Use of nucleotide sequence SEQ ID NO: 11 |
Use different nucleotide sequence (including synonymous changes) if it avoids SEQ ID NO: 11 |
| 6 |
Recombinant vector comprising SEQ ID NO: 11 |
Vector contains SEQ ID NO: 11 |
Use different genetic element sequence |
| 7 |
Vector selected from plasmid/cosmid/phage/virus DNA |
Vector type category still containing SEQ ID NO: 11 |
Switch genetic sequence; vector category alone likely insufficient |
| 8 |
Host organism transformed by recombinant vector of claim 6 |
Host carries vector with SEQ ID NO: 11 |
Avoid inclusion of SEQ ID NO: 11 |
| 9 |
Host is virus/bacteria/yeast/fungus/plant/mammalian cell |
Host taxonomy |
Not a likely lever if the vector sequence is present |
| 10 |
Composition with nucleic acid SEQ ID NO: 11 and/or vector with SEQ ID NO: 11 + vehicle |
Use of SEQ ID NO: 11 nucleic acid/vector as active |
Avoid SEQ ID NO: 11 literal sequence |
| 11 |
Composition with nucleic acid coding SEQ ID NO: 12 + vehicle |
Active nucleic acid coding the peptide |
Avoid SEQ ID NO: 11 if the claim is intended to be literal; otherwise avoid SEQ ID NO: 12-coding element |
What is the patent landscape around US 8,168,593: continuation/divisional/related families and adjacent sequence claims?
Answer constrained by missing bibliographic family information. Comprehensive landscape requires at least the patent’s title, assignee, priority date, and related applications. The claim text alone does not permit a complete and accurate mapping of:
- continuations/divisionals,
- overlapping sequence claims,
- related method-of-treatment or manufacturing claims in the same family.
Key Takeaways
- US 8,168,593 is a sequence-defined protection regime for a specific Netrin-4 fragment: peptide SEQ ID NO: 12 and its corresponding nucleotide sequence SEQ ID NO: 11.
- The patent’s highest enforcement value is directed at any product whose active ingredient literally uses those sequences, including peptide formulations and nucleic-acid/gene delivery constructs.
- The anti-VEGF combination claim (Claim 3) creates licensing leverage because anti-VEGF agents are well-established, but infringement still requires use of the SEQ ID NO: 12 peptide as the active ingredient in the claimed composition.
- Design-around is most viable by changing peptide sequence boundaries (Claim 1/2/3/11) and/or using non-identical nucleotide sequences to avoid SEQ ID NO: 11 (Claim 5 and all constructs derived from Claim 5/6/10).
FAQs
- Can a competitor avoid US 8,168,593 by using a synonymous coding DNA that still produces SEQ ID NO: 12 peptide?
- Does US 8,168,593 cover delivery vehicles like viral vectors if they contain SEQ ID NO: 11?
- If a product includes SEQ ID NO: 12 peptide but combines anti-VEGF by co-administration rather than in one formulation, does Claim 3 still read?
- Would an antibody that binds Netrin-4 infringe if it does not include SEQ ID NO: 12 peptide or SEQ ID NO: 11 nucleic acid?
- How should a developer map its candidate’s peptide and coding sequence to SEQ ID NO: 12 and SEQ ID NO: 11 to assess infringement risk?
References
- United States Patent 8,168,593 (claims as provided in prompt).
More… ↓
⤷ Start Trial
|
